If deemed to meet the reasonable and necessary criteria, Medicare may - for lecanemab - remove the conditional access barrier it imposed on all beta amyloid-directed monoclonal antibodies in the National Coverage Determination (NCD) issued in April of ...
VIEW MORE : https://bit.ly/1breakingnews
